Using psychedelics to treat chronic pain is understudied yet full of potential.
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Understanding the structure of this synthetic analog of 5-MeO-DMT may help explain the effects of naturally occurring chemical cocktails.
New crystalline forms of norpsilocin create new options for developing psychedelic drug formulations.
Understanding brain morphology differences may prove essential for creating effective psychedelic drug formulations.
Environment and diet may play a role in the alkaloid content of secretions from a Brazilian toad species.
Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Pain was inhibited by an α2-adrenoceptor antagonist and reduced by an α1-adrenoceptor antagonist. Opioid receptors may also be involved in the effects.